Showing results (81-90 of 279) with videos related to

Sort By:
Pageof 28
Science Translational Medicine|May 20, 2016
Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALLScott McComb, Júlia Aguadé-Gorgorió, Lena Harder, et al.
Pediatric Blood & Cancer|September 22, 2012
Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemiaJana Volejnikova, Ester Mejstrikova, Petra Dörge, et al.
Blood|March 16, 2010
CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemiaPeter Rhein, Rita Mitlohner, Giuseppe Basso, et al.
Therapeutic Drug Monitoring|February 6, 2020
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 StudyGudrun Würthwein, Claudia Lanvers-Kaminsky, Joachim Gerss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90Gesche Tallen, Richard Ratei, Georg Mann, et al.
Haematologica|April 22, 2006
Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion geneMarkus Metzler, Georg Mann, Uli Monschein, et al.
British Journal of Haematology|October 14, 2009
Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elementsAndishe Attarbaschi, Markus Pisecker, Andrea Inthal, et al.
Blood|September 25, 2004
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemiaGunnar Cario, Martin Stanulla, Bernard M Fine, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2014
Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancerGilles Vassal, Raphaël Rousseau, Patricia Blanc, et al.
Pediatric Blood & Cancer|August 31, 2018
Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patientsMeinolf Suttorp, Markus Metzler, Frederic Millot, et al.
Pageof 28